Morphic Holding, Inc. (MORF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is Praveen P. Tipirneni.
MORF has IPO date of 2019-06-27, 128 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $2.86B.
Morphic Holding, Inc. is a biopharmaceutical company focused on discovering and developing oral small-molecule integrin therapeutics to treat autoimmune, cardiovascular, metabolic, fibrotic, and oncologic diseases. The company's lead candidate, MORF-057, is an α4β7-specific integrin inhibitor currently in Phase 1 clinical trials for inflammatory bowel disease, with preclinical programs targeting idiopathic pulmonary fibrosis and other fibrotic conditions. Morphic is also advancing programs in αvβ6 for fibrotic diseases and αvβ8 for solid tumors through its proprietary integrin technology platform. The company has established research collaborations and licensing agreements with major partners including AbbVie, Janssen Pharmaceuticals, and Children's Medical Center Corporation to accelerate integrin-based drug development. Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic leverages its integrin technology expertise to address significant unmet medical needs across multiple therapeutic areas.
